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Background: Diabetes remains a significant risk factor for restenosis/thrombosis following stenting. Although
vascular healing responses following drug-eluting stent (DES) treatment have been characterized previously in
healthy animals, comparative assessments of different DES in a large animal model with isolated features of
diabetes remains limited. We aimed to comparatively assess the vascular response to paclitaxel-eluting (PES) and
everolimus-eluting (EES) stents in a porcine coronary model of streptozotocin (STZ)-induced type I diabetes.
Method: Twelve Yucatan swine were induced hyperglycemic with a single STZ dose intravenously to ablate
pancreatic β-cells. After two months, each animal received one XIENCE VW (EES) and one Taxus Liberte (PES) stent,
respectively, in each coronary artery. After three months, vascular healing was assessed by angiography and
histomorphometry. Comparative in vitro effects of everolimus and paclitaxel (10-5 M–10-12 M) after 24 hours on
carotid endothelial (EC) and smooth muscle (SMC) cell viability under hyperglycemic (42 mM) conditions were
assayed by ELISA. Caspase-3 fluorescent assay was used to quantify caspase-3 activity of EC treated with everolimus
or paclitaxel (10-5 M, 10-7 M) for 24 hours.
Results: After 3 months, EES reduced neointimal area (1.60 ± 0.41 mm, p< 0.001) with trends toward reduced %
diameter stenosis (11.2 ± 9.8%, p = 0.12) and angiographic late-loss (0.28 ± 0.30 mm, p = 0.058) compared to PES
(neointimal area: 2.74 ± 0.58 mm, % diameter stenosis: 19.3 ± 14.7%, late loss: 0.55 ± 0.53 mm). Histopathology
revealed increased inflammation scores (0.54 ± 0.21 vs. 0.08 ± 0.05), greater medial necrosis grade (0.52 ± 0.26 vs.
0.0 ± 0.0), and persistently elevated fibrin scores (1.60 ± 0.60 vs. 0.63 ± 0.41) with PES compared to EES (p< 0.05). In
vitro, paclitaxel significantly increased (p< 0.05) EC/SMC apoptosis/necrosis at high concentrations (≥10-7 M), while
everolimus did not affect EC/SMC apoptosis/necrosis within the dose range tested. In ECs, paclitaxel (10-5 M)
significantly increased caspase-3 activity (p< 0.05) while everolimus had no effect.
Conclusion: After 3 months, both DES exhibited signs of delayed healing in a STZ-induced diabetic swine model.
PES exhibited greater neointimal area, increased inflammation, greater medial necrosis, and persistent fibrin
compared to EES. Differential effects of everolimus and paclitaxel on vascular cell viability may potentially be a
factor in regulating delayed healing observed with PES. Further investigation of molecular mechanisms may aid
future development of stent-based therapies in treating coronary artery disease in diabetic patients.
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The prevalence of diabetes is quickly increasing in both
developing and developed countries, with the number of
diabetic patients expected to increase to 366 million
people (4.4% prevalence) globally by 2030 [1]. Coronary
artery disease is highly prevalent in diabetic patients and
is a major cause of mortality in patients with both type I
and type II diabetes [2]. Though the incidence of in-
stent restenosis following drug-eluting stent (DES)
treatment is greater in diabetic patients compared to
non-diabetic patients, several clinical studies have
suggested improved prognosis following percutaneous
interventions for treatment of coronary and peripheral
artery disease in diabetic patients [3,4]. Although the use
of DES for treatment of coronary artery disease in
patients with diabetes has increased, limited data exists
on comparing the vascular responses of different DES in
relevant preclinical models of diabetes.
Diabetic patients with coronary artery disease exhibit
factors such as hyperglycemia, hyperinsulinemia,
hypercholesterolemia, insulin resistance, and increased
inflammation [1]. The streptozotocin (STZ)-induced
diabetic swine has been described as insulin-controlled
hyperglycemia analogous to a type-I diabetic condition.
It tends to exhibit increased inflammation but not
atherosclerosis [5]. Factors related to insulin resistance
and hypercholesterolemia likely differ from a human
type II diabetic condition. Other factors important to
stenting previously connected to hyperglycemia include
increased thrombus and neointima formation [6,7],
dysfunctional endothelial cells [8], and impaired wound
healing [9] and have previously been demonstrated in
this model. Although type I diabetes constitute ~10% of
all patients with diabetes, type I diabetics at a young age
(≤ 40) may be at high risk for development of severe
coronary artery disease [10], and only a few studies have
investigated coronary stenting in relevant animal models
of type I diabetes.
Preclinical studies have previously characterized vessel
healing responses to bare-metal stents (BMS) in STZ-
induced type I diabetic animal models and have
established delayed healing responses following BMS
treatment in STZ animals compared to non-diabetic
controls [6,11]. More recent studies have begun to assess
the vascular responses of commercially available DES in
animal models of type I diabetes. In a STZ rat model
comparing first generation sirolimus-eluting stents with
paclitaxel-eluting stents (PES), histomorphometric
analysis revealed increased thrombus, inflammatory cell
infiltration, and neointimal hyperplasia with DES
treatment in STZ rats four weeks after aortic stenting
compared to non-STZ controls [12]. DES in STZ rats
were associated with delayed re-endothelialization,
increased fibrin deposition, and changes in extracellularmatrix composition compared to DES in non-STZ rats.
Although this study was the first study to report
comparative effects of DES in a STZ type I diabetic
model, use of a large animal model of type I diabetes are
advantageous for stent evaluation compared to a small
animal model due to development of features with more
reliable pathophysiological resemblance to human
diabetes and anatomical similarities in vessel size, allow-
ing for assessment of stenting in coronary arteries rather
than other vessels with different tissue architecture and
flow environments. It has been demonstrated that
6 months after sirolimus-eluting stent implantation in
coronary arteries of minipigs with STZ-induced diabetes,
the degree of in-stent restenosis, late lumen loss, and
neointimal hyperplasia were significantly increased
compared to sirolimus-eluting stents in nondiabetic
controls [7].
Since previous studies have established delayed healing
with both BMS and DES in STZ swine compared to
non-STZ controls, we aimed to specifically compare for
the first time the in vivo vascular response to PES and
everolimus-eluting stents (EES) after 90 days in a
porcine coronary model of STZ-induced type I diabetes.
Paclitaxel is an antineoplastic, lipophilic molecule [13].
Everolimus acts as an antiproliferative and immunosup-
pressive agent [14]. Vascular responses to PES and EES
were assessed by angiography and histomorphometry.
To evaluate potential effects of drugs alone on vascular
cell viability in support of in vivo assessment of DES in
hyperglycemic swine, in vitro effects of paclitaxel and
everolimus on endothelial cell (EC) and smooth muscle




All experimentation conformed to the Animal Welfare
Act and the Guide for Care and Use of Laboratory
Animals (NIH Publication 85–23, 1996) and the Canad-
ian Council on Animal Care regulations. All procedures
were performed at AccelLab, Inc (Boisbriand, Quebec,
Canada), accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care and in
accordance with the protocol approved by the Institu-
tional Animal Care and Use Committee.
STZ-induced diabetic porcine model
Twelve Yucatan swine were administered a single dose
of STZ (125 mg/kg body weight, Sigma-Aldrich, St.
Louis, MO) intravenously to ablate pancreatic β-cells,
and blood glucose was monitored daily. Two to three
days following STZ injection, daily insulin was used to
moderate the increase in fasting glucose from normal
(~2 mmol/L) to a target level of 20–23 mmol/L over the
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(LantusW) and regulator-acting (Novalin GE TorontoW)
insulin and maintained elevated thereafter. Insulin was
administered approximately 1 hour after feeding, thus
not during fasting prior to procedures.
Intracoronary stenting
Two months following diabetes induction, stents were
implanted and randomized to the left anterior descend-
ing (LAD), left circumflex (LCX), or right coronary
arteries (RCA) (one stent deployed per artery). A total of
22 stents were deployed: XIENCE VW everolimus-eluting
stents (EES, 3.0x12mm, Abbott Vascular, Santa Clara,
CA, n = 11) or Taxus Liberte paclitaxel-eluting stents
(PES, 3.0x12mm, Boston Scientific, Natick, MA, n = 11).
The number of stents was equally divided amongst the
three arteries (for EES and PES, 4 in LAD, 3 in LCX,
and 4 in RCA), with placement of stents within coronary
arteries similar for all groups. However, stents were not
implanted in the exact same anatomical locations within
each coronary artery (e.g. after first diagonal) but were
implanted based upon similar artery size. There were
only 11 arteries evaluated per treatment group, as arter-
ies less than 2.6 mm in diameter were excluded to en-
sure a stent-to-artery ratio of 1.1:1 and full apposition of
all stents was achieved angiographically in all coronaries
devoid of major side branches.
Procedure
Animals were administered oral acetylsalicylic acid
(325 mg) and clopidogrel (300 mg initial dose and
75 mg subsequently) beginning three days prior to stent
implantation and continuing daily until sacrifice.
Animals were tranquilized with ketamine (0.04 mg/kg),
azaperone (4.0 mg/kg), and atropine (25 mg/kg) intra-
muscularly. Anesthesia was achieved with propofol
(1.66 mg/kg IV), and maintained with isofluorane (1-3%)
throughout the procedure. A vascular access sheath was
placed in the femoral artery percutaneously. Before
catheterization, heparin (400U/kg) was injected to main-
tain an activated clotting time >300 s. At three months
post-stenting, follow-up angiography was performed.
Three months was chosen as the earliest time point at
which differences in arterial healing response between
DES may emerge [15] and because 90 days in swine has
been suggested to correspond to >1 year in humans
[16]. Animals were euthanized under general anesthesia.
Hearts were excised and pressure-perfused with 0.9%
saline followed by pressure-perfusion fixation in 10%
neutral buffered formalin.
Animal health
Blood was collected prior to diabetes initiation, at stent
implant, and prior to follow-up angiography for serumbiochemistry and hematology (Marshfield Laborator-
ies, Marshfield, WI). Upon termination, gross necropsy
was performed and samples of the kidney, lung, liver,
and pancreas were stained with hematoxylin and eosin
(H&E) and evaluated by a trained pathologist. Obser-
vations of the kidney, liver, lung, and pancreas were
noted at necropsy and from histopathological assess-
ment of H&E stained tissue sections using light
microscopy. Pathophysiological observations in each
tissue were described and when applicable received a
subjective score (0 = absent or not present, 1 =mild,
2 =moderate, 3 =marked) following evaluation of H&E
tissue staining from the blinded study pathologist.
Histological assessment of stented coronary artery tissue
in STZ-induced diabetic porcine
The fixed stented arterial segments were dehydrated in
a graded series of ethanol and embedded in methyl
methacrylate resin. For each stent, three sections
(proximal, middle, and distal) were cut on a rotary
microtome (~5 μm thickness) and stained with H&E
and elastic Van Gieson stains. Proximal and distal
sections to the stented region were stained with H&E.
The cross-sectional areas (internal elastic lamina (IEL)
and lumen) of each section were measured using digital
morphometry software (Image Pro, Media Cybernetics,
Bethesda, MD). Neointimal area was measured on
elastin stained sections. The IEL was traced as was the
lumen, and the neointimal area was calculated as the
IEL area minus lumen area. Histopathology scoring of
pre-specified criteria for: injury [17], inflammation,
fibrin, and neointimal immaturity was performed on a
0–3 scale by a trained pathologist independent of the
study sponsor through blind review and peer-reviewed
by a second pathologist. For inflammation and fibrin, a
score of 0 indicated absent or rare occurrence around a
strut, while a score of 3 indicated most severe around a
strut as well as abundant between struts in surrounding
tissue. Neointimal immaturity scoring was based upon
the proportion of area with immature healing and
organization in response to stenting. Less mature areas
were scored as 3 and identified as containing few to no
myofibroblasts, a high proportion of mucinous matrix,
edema, or fibrin, and undifferentiated mesenchymal cells
or inflammatory cells.
Histopathological samples were evaluated semi-quanti-
tatively for strut/IEL gap, peri-strut hemorrhage, peri-
strut plasma, marginated/subendothelial leukocytes,
neointimal neovascularization, medial necrosis, adventi-
tial inflammation, and adventitial fibrosis by a blinded
study pathologist independent of the study sponsor and
peer-reviewed by a second pathologist via hematoxylin
and eosin (H&E)/Van Gieson stained stented arterial
segments using light microscopy. Observations were
Table 1 Assessment of blood serum chemistry




Bilirubin 0.31 ± 0.28 μM 4.40 ± 2.43 μM * 1.42 ± 1.23 μM *
Blood Urea
Nitrogen
5.4 ± 1.1 mM 7.0 ± 1.0 mM * 8.4 ± 2.7 mM *
Serum Creatinine 72 ± 15 μM 105± 45 μM * 91± 30 μM *
Swine were healthy through the remainder of the study with only altered
blood work related to diabetes: n = 12. * p< 0.05 vs. baseline.
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2 =moderate, 3 =marked) when applicable, or the
percentage of struts affected was enumerated. The
incidence of each observation, or when applicable, the
group mean score, was tabulated and reported by stent
group.
In vitro effects of paclitaxel and everolimus on SMC and
EC apoptosis/necrosis
EC and SMC were harvested from carotid artery of
Yucatan swine with an enzymatic digestion procedure
described previously [18] and cultured in Dulbecco’s
Modified Eagle Medium (DMEM) media (Lonza,
Walkersville, MD) supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin (Invitro-
gen, Carlsbad, CA). Cells were cultured in a 37°C and
5% CO2 environment, and all experiments were
performed using cells at passage 6 or lower. EC were
immunohistologically characterized by positive
PECAM-1/CD31 (Abcam, Cambridge, MA) staining,
while SMC were characterized by positive SM actin,
SM myosin, and calponin (all Dako, Carpinteria, CA)
staining (data not shown).
To assess the effects of everolimus and paclitaxel on
EC and SMC viability, total cell necrosis and induction
of apoptosis were evaluated using a Cell Death Detection
ELISAPLUS kit (Roche Applied Science, Mannheim,
Germany), with an endpoint of absorbance (A405nm –
A490nm) read on a M5 Spectramax plate reader (Molecu-
lar Devices Corporation, Sunnyvale, CA) according to
manufacturer’s specifications. On Day 0, EC or SMC
were seeded in 24-well plates (Costar, Lowell, MA) and
allowed to grow to 80% confluence under high glucose
conditions (42 mM, Sigma-Aldrich) similar to hypergly-
cemic levels used in previous studies [19,20]. Cells were
then treated with dimethyl sulfoxide (DMSO, Sigma-
Aldrich) vehicle control, everolimus (Novartis, Basel,
Switzerland), or paclitaxel (Sigma-Aldrich) over a range
of concentrations (10-5 M–10-12 M), or growth media
alone (control) for 24 hours. Following treatment, cell
media supernatants were collected, cultures were
washed with PBS, and cells were treated with lysis buffer
supplied in ELISA kit. ELISA detection of histone-asso-
ciated nucleosome concentration in cell media superna-
tants was used to determine overall necrosis, while
concentration in cell lysates was used to determine
relative induction of apoptosis, all according to manufac-
turer’s instructions. A caspase-3 fluorescent assay kit
(Clontech Laboratories, Mountain View, CA) was used
to quantify caspase-3 activity of EC cultured under high
glucose conditions (42 mM) and treated with everolimus
or paclitaxel (10-5 M, 10-7 M) for 24 hours. Total protein
content of cell lysates was determined using Bradford
DC Protein assay (Bio-Rad Laboratories, Hercules, CA),with an endpoint of absorbance (A750nm) read on an M5
Spectramax plate reader. Apoptosis, necrosis, and cas-
pase-3 activity data for each sample were normalized to
respective total protein content and expressed as fold
change relative to control samples.
Statistical analysis
All data are presented as mean± standard deviation un-
less otherwise specified. All data was analyzed according
to criteria pre-specified in the study protocol. For all
data, equal variance test and normality tests were
performed prior to other mean comparison testing. For
normal data, a one way analysis of variance (ANOVA)
was used with Holm’s post-hoc test to compare differ-
ences between groups. For non-parametric data, a
Wilcoxon rank-sum test was used to compare between
two samples. A p-value of p< 0.05 was considered




Following STZ injection, animals were hypoglycemic
below the threshold of detection (0.6 mmol/L). Within a
few days, animals became hyperglycemic and were
maintained hyperglycemic (10-23 mmol/L) throughout
the remaining 5 months. Animals had an average weight
loss of 11.1 ± 5.0 kg during the initial two months of
diabetes and stabilized thereafter (average gain
2.7 ± 6.4 kg). Animals exhibited altered blood serum due
to diabetes as summarized in Table 1. No other abnor-
mal blood work was observed. Based upon histopatholo-
gic evaluation following euthanasia, 9/12 swine had
evidence of mild to marked tubulointerstitial degener-
ation and 2/12 had chronic mild to moderate glomerulo-
sclerosis. Evidence of pancreatic β-cell atrophy was
observed in all animals.
QCA
All animals survived stent implantation and follow up
procedures without complication. There were no
differences between groups in pre-stent reference vessel
diameter or post-stent minimal lumen diameter (MLD)
as measured by QCA. Table 2 summarizes the QCA
Table 2 QCA assessment of coronary arteries
In stent Xience V Taxus p-value
Pre-Stent Mean Lumen Diameter 2.68 ± 0.19 2.79 ± 0.19 -
Balloon to artery ratio 1.16 ± 0.03* 1.10 ± 0.03 0.002
MLD, mm 2.40 ± 0.30 2.26 ± 0.50 0.25
Diameter stenosis, % 11.2 ± 9.8 19.3 ± 14.7 0.12
Binary restenosis, % 0 8.3 N/A
Late Loss, mm 0.28 ± 0.30 0.55 ± 0.53 0.058
MLD – Minimal lumen diameter. n = 11 for Xience V, n = 11 for Taxus.
* p< 0.05 vs. Taxus.
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increased late loss with PES (p = 0.058) in comparison to
EES.Histomorphometry
Histomorphometry confirmed trends observed by QCA.
PES displayed increased neointimal area (2.74 ± 0.58 mm,
n = 11) in comparison to EES (1.60 ± 0.41 mm, n = 11)
(p< 0.001). No significant differences in percent area
stenosis were observed between PES (37.9 ± 10.4%) and
EES (26.3 ± 8.0%) treatment groups. Complete histo-
morphometric findings are summarized in Table 3.Histopathology
Characteristics observed in both DES suggested delayed
healing in these STZ-induced type I diabetic animals in
comparison to our previous experience in healthy swine
as well as that of others [21]. There were no significant
differences in injury scores across the two devices (EES
0.18 ± 0.16, PES 0.09 ± 0.13, p = 0.279). Inflammation was
moderately increased in response to PES (0.54 ± 0.21,
n = 11) compared to EES (0.08 ± 0.05, p< 0.05 vs. PES,
n = 11) (Figure 1A). The predominant inflammatory in-
filtrate was macrophages with occasional multinucleated
giant cells. Fibrin scores were also significantly increased
(p< 0.05) with PES (1.60 ± 0.60) when compared to EES
(0.63 ± 0.41) (Figure 1B). Both DES exhibited neointimalTable 3 Histomorphometry assessment of coronary
arteries 3 months post-stenting in STZ-induced diabetic
swine
Xience V Taxus p-value
EEL Area (mm2) 7.33 ± 0.92 * 8.44 ± 0.88 0.022
IEL Area (mm2) 6.22 ± 0.77 * 7.35 ± 0.74 0.005
Medial Area (mm2) 1.12 ± 0.23 1.09 ± 0.22 -
Intimal Area (mm2) 1.60 ± 0.41 * 2.74 ± 0.58 <0.001
Luminal Area (mm2) 4.62 ± 0.94 4.61 ± 1.06 -
Area Stenosis (%) 26.3 ± 8.0 37.9 ± 10.4 -
EEL – External elastic lamina. IEL – Internal elastic lamina. n = 11 for Xience V,
n = 11 for Taxus. * p< 0.05 vs. Taxus.immaturity (Figure 1C), with no significant differences
observed between EES (1.06 ± 0.67) and PES
(1.64 ± 0.69). Immature neointima was characterized by
marginated subendothelial leukocytes, amorphous fibrin,
and peri-strut hemorrhage and hemosiderin deposits.
Table 4 characterizes the composition and distribution
of histopathologic findings. In PES, fibrin created a gap
between the IEL and the strut in 7 of 11 vessels in ap-
proximately 1/3 of the struts. Medial necrosis was
greater in PES struts in comparison to EES (Table 4,
Figure 2). In EES, accumulation of homogenous pale eo-
sinophilic material was present around the struts (11/11
vessels) while infrequent in PES (3/11 vessels). This fluid
rarely contained cells and was interpreted as extra-cellular
fluid of blood plasma origin.
In vitro effects of everolimus and paclitaxel on EC and
SMC apoptosis/necrosis
SMC were cultured in high glucose conditions to ascer-
tain effects of everolimus and paclitaxel on apoptosis
and secondary necrosis. After 24 hours, quantitative
measurement of apoptosis from cellular lysates revealed
everolimus did not significantly increase SMC apoptosis
at any dose tested (10-5 M-10-12 M, n = 3) compared to
controls (Figure 3A). Paclitaxel significantly increased
apoptosis of SMC from STZ swine at both 10-5 M
(4.75 ± 1.17-fold, p< 0.05) and 10-6 M (2.77 ± 0.38-fold, p
< 0.05) compared to controls and everolimus-treated
groups. Similar results were obtained when cell media
supernatants were analyzed to assess drug effects on
SMC necrosis (Figure 3A).
Experiments to examine the effects of everolimus and
paclitaxel on apoptosis and necrosis of EC under high
glucose conditions revealed similar trends in drug effects
as those observed in SMC (Figure 3B). Compared to
SMC, EC appeared to be more sensitive to paclitaxel
treatment. At 10-7 M paclitaxel, elevated apoptosis/ne-
crosis was observed in EC but not in SMC, and the ex-
tent of apoptosis/necrosis was greater in EC compared
to SMC in response to paclitaxel at higher concentra-
tions (Figure 3A and 3B). Paclitaxel, but not everolimus,
at 10-5 M (n = 3, p< 0.05) significantly upregulated cas-
pase-3 in ECs, suggesting that paclitaxel-induced EC
apoptosis was caspase-3 dependent (Figure 4).
Discussion
In the present study, we compared the coronary arterial
healing to paclitaxel- and everolimus-eluting stents in a
porcine model of STZ-induced type I diabetes in non-
overlapping segments 90 days following stent implant-
ation and investigated in vitro drug effects on EC and
SMC viability. The main findings of our study were: 1)
in the presence of chronic hyperglycemia, in comparison

























Figure 1 Histological assessment of coronary artery tissue stented with PES and EES in STZ-induced type I diabetic swine.
Histopathological scoring (mean± standard deviation, n = 11) revealed delayed neointimal healing in response to PES after 90 days. Both A)
inflammation and B) fibrin were significantly increased in response to PES (Taxus) (p< 0.05) compared to EES (Xience V). C) No significant
differences in neointimal immaturity were found between PES and EES. * p< 0.05.
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timal area, increased inflammation, greater medial ne-
crosis, and persistent fibrin, after 3 months and 2)
paclitaxel, unlike everolimus, significantly increased EC
and SMC apoptosis/necrosis in vitro at high concentra-
tions (≥10-7 M) under hyperglycemic culture conditions.Table 4 Histopathology composition and distribution of
findings
Xience V Taxus
Strut/IEL gap Incidence 1/11 7/11
Percentage 5.6 36.9 ± 32.9
Peri-strut hemorrhage Incidence ———— 2/11
Percentage ———— 11.3 ± 10.7
Peri-strut plasma Incidence 11/11 3/11
Grade 1.35 ± 20.6 0.78 ± 0.39
Marginated/subendothelial leukocytes Incidence 4/11 10/11
Grade 0.46 ± 0.16 1.00 ± 0.52
Neointimal neovascularization Incidence ———— 5/11
Grade ———— 0.80 ± 0.18
Medial necrosis Incidence ———— 7/11
Grade ———— 0.52 ± 0.26
Adventitial inflammation Incidence ———— 1/11
Grade ———— 0.33
Adventitial fibrosis Incidence ———— ————
Grade ———— ————
Incidence results are presented as # of stents with findings/total number of
stents.
Mean grade or percentage results are presented as mean grade or percentage
of affected struts per group± standard deviation.
n = 11 for Xience V, n = 11 for Taxus.Animal health
Overall, animals remained in good health throughout
the study with systemic abnormalities that were attribut-
able to type I diabetes induction including alterations to
blood proteins and changes in the kidney. The observed
histopathological changes in the kidney were indicative
of early stages of diabetic nephropathy [22].In vivo histopathology
Histopathologically, percent stenosis was found to be nu-
merically greatest but not significantly different in PES in
comparison to EES. One of the first histopathologic eva-
luations of PES deployed in rabbit iliac arteries demon-
strated a reduction in mean neointimal thickness at
28 days but not at 90 days [23]. Similarly, in healthy swine,
PES have demonstrated decreased neointima at 30 days
but not 90 days [21]. Pathology of arteries stented with
PES has characterized the neointima as containing persist-
ent intimal fibrin deposition, intraintimal hemorrhage, and
increased inflammation [23]. Increased fibrin deposition
associated with PES has also been reported following
stenting in human coronary arteries [24]. Interestingly, in
a reported dose dependent study [23], the histologic find-
ings of delayed healing were not present in the lower dose
PES group, suggesting that drug effect was a primary cul-
prit in the pathology herein. Other researchers have simi-
larly reported on the significant delayed healing in stents
eluting paclitaxel in healthy rabbits [25] and swine [26].
Most recently, in a diabetic/hypercholesterolemic porcine
model, the coronary responses to BMS and PES implant-
ation were reported to display increased inflammation
with SMC loss and persistent fibrin out to 90 days [27].
Compared to BMS, PES also exhibited increased neointi-
mal area and delayed reendothelialization. Similar to these
Figure 2 Histopathology of coronary artery tissue stented with PES and EES in STZ-induced type I diabetic swine. Representative
histopathological microscopy images (20x) of coronary arteries stented with EES (Xience V) and PES (Taxus) and stained with H&E after 90 day
implantation.
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cholesterolemia, PES exhibited increased neointima and
delayed healing in comparison to an everolimus-eluting
stent.
The findings following stenting with an everolimus-elut-
ing stent support previous published work with this device
as well. Low inflammation and endothelialization have
been reported following everolimus-eluting stent implant-
ation in healthy rabbits [28] and swine [29,30] as well as in
atherosclerotic rabbits [31]. Other investigators have
described the vessel healing response to everolimus-elut-
ing stents in overlap configurations as well [32]. In par-
ticular, the presence of fibrin following stenting with
everolimus-eluting stents was not different than bare
metal stents 90 days following stenting in a porcine model
in single and overlap configurations. The data in the
present study suggest that the EES continues to heal in
spite of chronic hyperglycemia out to 90 days in a swine
model. Fibrin was observed to be minimal at 90 days with
inflammation almost completely resolved.
In addition to previous findings reported with these
stents, we report here an additional description of
increased neovascularization in PES, which is a common
finding following thrombus/fibrin accumulation and ac-
companied inflammation and has been suggested to be
directly related to the early phases of thrombus healing[33]. The EES vessels occurred without significant neo-
vascularization, likely the result of less fibrin
reorganization earlier in the healing process. The inflam-
matory response to both PES and EES primarily charac-
terized as para-strut macrophages with occasional giant
cells and few lymphocytes has been characterized previ-
ously as the predominant inflammatory response to
stenting [34,35] in humans. The magnitude rather than
the composition of inflammation represents the differen-
tial inflammatory response to these two devices. Peri-
strut eosinophilic material interpreted as plasma due to
its morphology, staining, and paucity of cells was found
most frequently in EES and has seldom been reported
pathologically following stenting. This finding may be an
indication of endothelial cell leakage from an immature
endothelial cell layer. Additional research is warranted
to understand the temporal differences in healing follow-
ing stenting with everolimus-eluting stents in a diabetic
swine model as well as the effects of hypercholesterol-
emia in comparison to a healthy model.
Differential effects of everolimus and paclitaxel on EC and
SMC apoptosis/necrosis
Since our in vivo comparison of vascular responses to
PES and EES was solely limited to STZ swine, we solely
characterized potential differences of drug alone on
Figure 3 Effects of paclitaxel and everolimus on SMC and EC apoptosis and necrosis. SMC or EC were cultured in vitro under
hyperglycemic conditions (42 mM) in 24-well plates and allowed to grow to 80% confluence. Cells were then treated with growth media alone
(control), DMSO vehicle control, or everolimus or paclitaxel over a range of concentrations (10-5 M–10-12 M) for 24 hours. A Cell Death Detection
ELISAPLUS kit was then used to detect histone-associated nucleosome concentration in cell media supernatants to determine overall necrosis,
while concentration in cell lysates was used to determine relative induction of apoptosis. Data expressed as fold change relative to control
(mean± standard deviation, n = 3). A) Paclitaxel significantly increased SMC apoptosis and necrosis in a dose-dependent manner at
concentrations of 1 μM and greater. B) Paclitaxel significantly increased EC apoptosis and necrosis in a dose-dependent manner at concentrations
of 0.1 μM and greater. Everolimus did not increase SMC or EC apoptosis or necrosis at any dose tested. * p< 0.05 vs. control.
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ture conditions. In vitro, our results demonstrate differ-
ential effects of everolimus and paclitaxel on the viability
of ECs and SMCs cultured under high glucose condi-
tions. Everolimus did not affect apoptosis or necrosis of
EC or SMC, while paclitaxel significantly increased
apoptosis and necrosis of both EC and SMC at high
concentrations (≥10-7 M). Additionally, our datademonstrated that paclitaxel-induced apoptosis in ECs
under high glucose conditions may occur through cas-
pase-3 activation. Since the concentrations of paclitaxel
that were observed to impact EC and SMC viability are
potentially achievable through local stent-based delivery
[36,37], the differential effects of these drugs on EC and
SMC viability may be a contributing factor to the
delayed healing of PES we observed in STZ-induced
Figure 4 Effects of paclitaxel and everolimus on caspase-3 activity in EC. EC were cultured in vitro under hyperglycemic conditions (42 mM)
and allowed to grow to 80% confluence. Cells were then treated with growth media alone (control), or everolimus or paclitaxel (10-5 M, 10-7 M)
for 24 hours. A caspase-3 fluorescent assay kit was used to quantify caspase-3 activity. Data expressed as fold change relative to control
(mean± standard deviation, n = 3). Paclitaxel increased EC caspase-3 activity in a dose-dependent manner while everolimus had no effect.
* p< 0.05 vs. control.
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has been found to regulate the cytotoxicity of vascular
cells under non-hyperglycemic culture conditions [38].
Increased SMC apoptosis/necrosis can increase cellular
debris, induce inflammation, and increase risk of throm-
bosis [39]. Dose-dependent effects of paclitaxel have
been shown to increase fibrin deposition and medial ne-
crosis following PES treatment in rabbit and porcine
models [23,40], which mirror our histopathological
observations with PES exhibiting both greater medial ne-
crosis and fibrin score compared to EES. Investigators
have linked paclitaxel-induced apoptosis [41] to p-Akt
reduction in SMC and speculated that Akt may play a
vasoprotective role in the histopathologic response to
stenting in diabetes [11]. Hypoactivation of Akt has been
previously linked with increased cell proliferation,
increased inflammation, and decreased cell viability
[5,11,42]. In ECs, the decrease in cell viability due to
paclitaxel treatment was correlated with a decrease in
caspase-3 activity, which potentially may be attributed to
the Akt pathway through Gas6-Axl interactions, as has
been shown previously in human umbilical vein EC [43].
Further cell culture viability studies are needed to eluci-
date if similar links between Akt and downstream cas-
pase-3 activation occur in response to these drugs under
hyperglycemic culture conditions.
Despite our in vitro observations on the effects of
drugs alone on vascular cell viability and the correlation
with in vivo observations, it is important to recognize
that DES systems are complex and consist of multiple
components. Therefore, we cannot solely attribute the
differences in vascular responses observed in vivo be-
tween PES and EES to drug effects alone, as the exact
mechanisms for the apparent differences observed aremost likely multifactorial. Though our in vitro data indi-
cate that drug may be a contributing factor in causing
the histologic differences observed between PES and
EES, other contributing factors could include differences
in coating, drug release kinetics, drug dose levels, stent
configuration impacting blood flow, strut thickness, de-
gree of hyperglycemia, and anatomical lesion location.
For instance, based upon previous studies, polymer-free
DES exhibited decreased fibrin deposition and inflam-
mation compared with polymer-based DES coatings
[44]. The differences in inflammation observed with EES
compared with PES in our study may be attributable to
differences in coating. Different stent configurations and
strut thicknesses are capable of impacting EC growth
and subsequent endothelial coverage by impacting blood
flow and wall shear stress [28,45]. Further studies are
needed to better characterize the effects of these individ-
ual factors in regulating in vivo vascular response to
DES.
Study limitations
This study has several potential limitations. By using
STZ to induce diabetes in swine, we created a large ani-
mal model of type I diabetes with ablation of pancreatic
β-cells that shares clinical similarities of chronic hyper-
glycemia. However, type II diabetes represents a complex
mixture of additional systemic (obesity, hyperlipidemia,
hyperinsulinemia) components. Though no preclinical
model can completely mimic the complexity of human
disease, this study isolates the effects of hyperglycemia
in comparing the arterial response to different DES in a
large animal model. Since significant prior data exists in
evaluating DES response in healthy animal models, the
exclusion of healthy control animals in this study should
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goal of this study was to compare for the first time the
vascular responses of two commercially available DES
with differing drug mechanisms of action in a large dis-
eased animal model of diabetes. It is important to ac-
knowledge that although results from preclinical animal
models do not always correlate with clinical results due
to differences in vessel disease development in humans,
this study demonstrated the ability of using a STZ swine
model to characterize differential vascular responses be-
tween PES and EES. It should be noted that clinical
trials comparing EES to PES in diabetes have shown no
reduction in target lesion failure and target lesion revas-
cularization [46,47]. An area of future study will be to
evaluate delayed healing following stenting in other
complex models to better understand the contribution
of each factor to stent pathology. Lastly, though we
compared effects of paclitaxel and everolimus in vitro to
evaluate differential effects of drug alone on vascular cell
viability, it would be interesting to assess if similar
responses to drugs would be observed using arterial tis-
sue from a diabetic animal model.Conclusions
The porcine model of STZ-induced type I diabetes
allows insight into comparing the differential vascular
response to PES and EES in a chronic hyperglycemic
state. After 3 months, PES exhibited greater neointimal
area, increased inflammation, greater medial necrosis,
and persistent fibrin compared to EES. The differential
in vitro effects of paclitaxel in reducing SMC/EC viabil-
ity under high glucose conditions compared to everoli-
mus may contribute to the delayed healing observed
with PES in a STZ swine model. Further studies are
needed to assess the intracellular signaling mechanisms
involved in regulating differential vascular responses be-
tween DES in diabetic animal models, which would aid
future development and evaluation of stent-based ther-
apies in treating coronary artery disease in diabetic
patients.
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